Document Detail


Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
MedLine Citation:
PMID:  16801565     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Cardiovascular disease (CVD) risk is increased in type 2 diabetes. The purpose of this study was to assess the effect of 10 mg of atorvastatin versus placebo on CVD prevention in subjects with type 2 diabetes and LDL cholesterol levels below contemporary guideline targets. RESEARCH DESIGN AND METHODS: Subjects were randomly assigned to receive 10 mg of atorvastatin or placebo in a 4-year, double-blind, parallel-group study. The composite primary end point comprised cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, recanalization, coronary artery bypass surgery, resuscitated cardiac arrest, and worsening or unstable angina requiring hospitalization. RESULTS: A total of 2,410 subjects with type 2 diabetes were randomized. Mean LDL cholesterol reduction in the atorvastatin group over 4 years was 29% versus placebo (P < 0.0001). When we compared atorvastatin versus placebo, composite primary end point rates were 13.7 and 15.0%, respectively (hazard ratio 0.90 [95% CI 0.73-1.12]). In the subset of 1,905 subjects without prior myocardial infarction or interventional procedure, 10.4% of atorvastatin- and 10.8% of placebo-treated subjects experienced a primary end point (0.97 [0.74-1.28]). In the 505 subjects with prior myocardial infarction or interventional procedure, 26.2% of atorvastatin- and 30.8% of placebo-treated subjects experienced a primary end point (0.82 [0.59-1.15]). Relative risk reductions in fatal and nonfatal myocardial infarction were 27% overall (P = 0.10) and 19% (P = 0.41) and 36% (P = 0.11) for subjects without and with prior myocardial infarction or interventional procedure, respectively. CONCLUSIONS: Composite end point reductions were not statistically significant. This result may relate to the overall study design, the types of subjects recruited, the nature of the primary end point, and the protocol changes required because of changing treatment guidelines. For these reasons, the results of the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) did not confirm the benefit of therapy but do not detract from the imperative that the majority of diabetic patients are at risk of coronary heart disease and deserve LDL cholesterol lowering to the currently recommended targets.
Authors:
Robert H Knopp; Michael d'Emden; Johan G Smilde; Stuart J Pocock
Related Documents :
11520485 - Effectiveness of statins in acute coronary syndromes.
8676835 - Why are lipids not predictive of cardiovascular death in the dialysis patient?
8569595 - Measuring of cardiolipin antibodies and plasma lipids in different stages of coronary d...
9699905 - Improvement of coronary vasodilatation capacity through single ldl apheresis.
15590075 - Towards defining heart failure in adults with congenital heart disease.
12755555 - Lessons from the stroke prevention in atrial fibrillation trials.
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Diabetes care     Volume:  29     ISSN:  0149-5992     ISO Abbreviation:  Diabetes Care     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-06-27     Completed Date:  2006-11-01     Revised Date:  2007-10-05    
Medline Journal Info:
Nlm Unique ID:  7805975     Medline TA:  Diabetes Care     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1478-85     Citation Subset:  IM    
Affiliation:
Harborview Medical Center, 325 Ninth Ave., #359720, Seattle, WA 98104-2499, USA. rhknopp@u.washington.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Cardiovascular Diseases / mortality,  prevention & control*
Diabetes Mellitus, Type 2 / complications,  drug therapy*
Double-Blind Method
Female
Heptanoic Acids / adverse effects,  therapeutic use*
Humans
Male
Middle Aged
Pyrroles / adverse effects,  therapeutic use*
Risk Assessment
Treatment Outcome
Chemical
Reg. No./Substance:
0/Heptanoic Acids; 0/Pyrroles; 110862-48-1/atorvastatin
Comments/Corrections
Comment In:
Diabetes Care. 2006 Nov;29(11):2561; author reply 2561-2   [PMID:  17065709 ]
Curr Atheroscler Rep. 2007 Jan;9(1):46-7   [PMID:  17169245 ]
ACP J Club. 2006 Nov-Dec;145(3):62   [PMID:  17080974 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular...
Next Document:  The effect of glucose variability on the risk of microvascular complications in type 1 diabetes.